At the time of writing, Black Diamond Therapeutics Inc [BDTX] stock is trading at $2.87, up 4.74%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BDTX shares have gain 11.24% over the last week, with a monthly amount glided 16.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Raymond James started tracking the stock with Outperform rating on July 31, 2024, and set its price target to $20. On July 14, 2023, Piper Sandler initiated with a Overweight rating. Stifel upgraded its rating to a Buy and increased its price target to $10 on June 30, 2023. H.C. Wainwright upgraded its rating to a Buy but $11 remained the price target by the analyst firm on June 28, 2023. Wedbush upgraded its rating to Outperform for this stock on June 27, 2023, but kept the price target unchanged to $10. In a note dated March 29, 2022, Wedbush downgraded an Neutral rating on this stock.
For the past year, the stock price of Black Diamond Therapeutics Inc fluctuated between $1.20 and $6.75. Currently, Wall Street analysts expect the stock to reach $14.75 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $2.87 at the most recent close of the market. An investor can expect a potential return of 413.94% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -0.06%, Pretax Profit Margin comes in at 0.07%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.05 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.75 points at the first support level, and at 2.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.93, and for the 2nd resistance point, it is at 2.99.
Ratios To Look Out For
It is important to note that Black Diamond Therapeutics Inc [NASDAQ:BDTX] has a current ratio of 9.24. As well, the Quick Ratio is 9.24, while the Cash Ratio is 5.84. Considering the valuation of this stock, the price to sales ratio is 2.33, the price to book ratio is 1.15 and price to earnings (TTM) ratio is 46.52.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Mar 19 ’25 when 5.78 million shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Aug 28 ’24 to sell 0.22 million shares. Meanwhile, Former Employer David Epstein bought 50000.0 shares on Jul 31 ’24.
